ֱ

Entresto Boosts Sex in HF; Venom Antidote to Xa Drugs; Guilty Plea for FH Vagueness

— Recent developments of interest in cardiovascular medicine

MedpageToday

Physical and social patients with reduced ejection fraction improved on sacubitril/valsartan (Entresto), largely related to household chores and sex, in post hoc analysis of the PARADIGM-HF trial presented at the Heart Failure Society of America meeting. (Monthly Prescribing Reference)

: "the heart attack symptom you've never heard of -- but need to take seriously," says Reader's Digest.

The left a 27% rate of residual stenosis in moderate to severely calcified arteries below the knee and resulted in one grade B dissection among 20 patients treated in the Disrupt BTK study but no perforations, distal embolization, reflow complications, or abrupt closures. (Mass Device)

At , 66% had blood pressure under control. (National Health Statistics Reports)

declined in prevalence from 2004 to 2015 in the U.K., researchers reported in BMJ.

A compound engineered from snake venom, PseudoXa, may be an effective, according to a report in Nature Communications.

Aegerion Pharmaceuticals pled guilty in U.S. District Court to for people without homozygous familial hypercholesterolemia. "Aegerion instead sought to render the diagnosis of HoFH as vague and indefinite as possible in order to extend the product use to additional patient populations," according to the FDA. (PharmaTimes)

Can the Vivistim vagus nerve stimulation electrical implant when paired with rehabilitation exercise? A trial is underway to find out. (STAT Plus, subscription req'd)

New proposed standards and guidelines for are open for comment until Sept. 30, ahead of release in October. (Intersocietal.org)

The American Heart Association (AHA) released , one for clinicians and another for patients and caregivers. (Medical Xpress)

The Resonate family of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy devices got FDA approval for MRI-conditional use labeling, Boston Scientific .

The Abbott also got approval for MRI compatibility. (Medical Device and Diagnostics Industry Qmed)

The FDA Surmodics' 0.014-inch low-profile percutaneous transluminal angioplasty balloon dilation catheter, the company announced. (Nasdaq)

European regulators also expanded clearance of the beyond abdominal aortic aneurysms. (Mass Device)

A European regulatory committee recommended an update to the product summary for dabigatran (Pradaxa) to say that atrial fibrillation patients on 150 mg BID dosing . (Pharmabiz.com)

India's National Pharmaceutical Pricing Authority will leave in place the imposed earlier this year and review them again in February 2018. (LiveMint) It also let Abbott bioresorbable stents from the market there, Economic Times reports.

The NFL worked with the AHA to release another and teach them how the heart works.